Table 2. Response to treatment.
Best overall response–no. (%) | Pembrolizumab, N=26 (65%) Nivolumab, N=14 (35%) | Ipilimumab, N=40 |
---|---|---|
Complete response | 0 | 0 |
Partial response | 8 (20) | 4 (10) |
Stable disease | 15 (38) | 3 (8) |
Progressive disease | 17 (42) | 33 (82) |